logo
Share SHARE
FONT-SIZE Plus   Neg

Biogen: US And EU Regulators Accept Plegridy Marketing Applications For Review

Biogen Idec (BIIB) announced Friday that U.S. and EU regulatory authorities have accepted the marketing applications for the review of Plegridy (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis or MS.

The U.S. Food and Drug Administration or FDA has accepted Biogen Idec's Biologics License Application or BLA for marketing approval of Plegridy in the United States and granted the company a standard review timeline. The Marketing Authorisation Application or MAA of Plegridy for review in the European Union was also validated by the European Medicines Agency.

The regulatory applications included positive one-year results from the two-year global Phase 3 Advance study. The data demonstrated that PLEGRIDY met all primary and secondary endpoints by significantly reducing disease activity including relapses, disability progression and brain lesions compared to placebo, and showed favorable safety and tolerability profiles at one year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A hedge fund is an alternative investment fund that uses pooled funds from accredited individuals or institutional investors and invests these funds in different assets with a goal of generating high returns. Hedge funds are generally accessible only to accredited or qualified investors. They cannot... Off-price retailer TJX Companies, Inc. reported a nearly 2 percent increase in profit for the fourth quarter from last year, reflecting higher sales and customer traffic. Both revenue and earnings per share for the quarter beat analysts' expectations. The company forecast earnings for the first quarter below the Street estimates and projects fiscal 2018 earnings above their expectations. Shares of Airbus Group SE declined around 2 percent in the early morning trading in Paris after the aerospace and defense major reported a loss in its fourth quarter, compared to a profit last year, mainly due to a hefty charge related to the A400M programme. Revenues, however, increased from last year. Further, the company lifted its dividend, and said it expects higher adjusted ea
comments powered by Disqus
Follow RTT